AMGEN Inc
Research AMGEN Inc (AMGN) on Bullrun: valuation model: 2.0% overvalued, market cap USD 239.07B, P/E 27.5, dividend yield 2.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAMGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal2.0% overvalued
- Market capUSD 239.07B
- P/E27.5
- Dividend yield2.3%
- Financial periodQ2 2026
- RevenueUSD 10.05B
- Net incomeUSD 2.38B
- Free cash flowUSD 3.49B
- Gross margin72.0%
Valuation Snapshot
Bullrun's latest valuation model marks AMGEN Inc as 2.0% overvalued; latest market cap is USD 239.07B; P/E is 27.5; dividend yield is 2.3%.
Peer valuation comparison
Latest P/E is 27.47x versus a Healthcare sector median of 24.46x (12.3% above).
Latest dividend yield is 2.27% versus a Healthcare sector median of 2.11% (7.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 36.75B | USD 7.71B | USD 8.10B | 67.2% | 14.23 | USD 9.13B | USD 54.60B | USD 8.66B |
| FY2024 | USD 33.42B | USD 4.09B | USD 10.39B | 61.5% | 7.56 | USD 11.97B | USD 60.10B | USD 5.88B |
| FY2023 | USD 28.19B | USD 6.72B | USD 7.36B | 70.0% | 12.49 | USD 10.94B | USD 64.61B | USD 6.23B |
| FY2022 | USD 26.32B | USD 6.55B | USD 8.79B | 75.7% | 12.11 | USD 7.63B | USD 38.95B | USD 3.66B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 239.07B | 27.5 | 2.2% | 9.94 |
| 2025 | 2025-12-31 | USD 176.35B | 23.0 | 2.9% | 9.52 |
| 2024 | 2024-12-31 | USD 139.96B | 34.5 | 3.5% | 9 |
| 2023 | 2023-12-29 | USD 154.14B | 20.5 | 3.0% | 8.52 |
| 2022 | 2022-12-30 | USD 140.14B | 21.0 | 3.0% | 7.76 |
| 2021 | 2021-12-31 | USD 125.60B | 21.8 | 3.1% | 7.04 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 9.94 USD, yield 2.3%.
| Year | Dividends/share |
|---|---|
| FY2025 | 9.66 USD |
| FY2024 | 9.13 USD |
| FY2023 | 8.64 USD |
| FY2022 | 7.95 USD |
About AMGEN Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is AMGEN Inc overvalued or undervalued?
Bullrun's valuation model currently marks AMGEN Inc as 2.0% overvalued.
What is AMGEN Inc's market cap?
AMGEN Inc's market capitalization is USD 239.07B.
What is AMGEN Inc's P/E ratio?
AMGEN Inc's price-to-earnings (P/E) ratio is 27.5.
Does AMGEN Inc pay a dividend?
AMGEN Inc has a dividend yield of 2.3%.
What does AMGEN Inc do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients.